WO2008112325A3 - Treatment of autoimmune disorders - Google Patents

Treatment of autoimmune disorders Download PDF

Info

Publication number
WO2008112325A3
WO2008112325A3 PCT/US2008/003548 US2008003548W WO2008112325A3 WO 2008112325 A3 WO2008112325 A3 WO 2008112325A3 US 2008003548 W US2008003548 W US 2008003548W WO 2008112325 A3 WO2008112325 A3 WO 2008112325A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
autoimmune disorders
improved
ltbr
methods
Prior art date
Application number
PCT/US2008/003548
Other languages
French (fr)
Other versions
WO2008112325A2 (en
Inventor
Graham K. Farrington
Evan Beckman
Jeffrey L. Browning
Werner Meier
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Priority to CN2008800163410A priority Critical patent/CN101951940A/en
Priority to CA002680792A priority patent/CA2680792A1/en
Priority to JP2009553656A priority patent/JP5431171B2/en
Priority to EP08742126A priority patent/EP2139509A2/en
Publication of WO2008112325A2 publication Critical patent/WO2008112325A2/en
Priority to US12/560,257 priority patent/US8338376B2/en
Publication of WO2008112325A3 publication Critical patent/WO2008112325A3/en
Priority to US13/682,221 priority patent/US20130259861A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described.
PCT/US2008/003548 2006-10-20 2008-03-17 Treatment of autoimmune disorders WO2008112325A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2008800163410A CN101951940A (en) 2007-03-15 2008-03-17 The treatment of autoimmune disease
CA002680792A CA2680792A1 (en) 2007-03-15 2008-03-17 Treatment of autoimmune disorders
JP2009553656A JP5431171B2 (en) 2007-03-15 2008-03-17 Treatment of autoimmune disorders
EP08742126A EP2139509A2 (en) 2007-03-15 2008-03-17 Treatment of autoimmune disorders
US12/560,257 US8338376B2 (en) 2006-10-20 2009-09-15 Compositions comprising variant LT-B-R-IG fusion proteins
US13/682,221 US20130259861A1 (en) 2006-10-20 2012-11-20 Treatment of autoimmune disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91851807P 2007-03-15 2007-03-15
US60/918,518 2007-03-15

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2007/081761 Continuation-In-Part WO2008049053A2 (en) 2006-10-20 2007-10-18 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US12/446,041 Continuation-In-Part US8067375B2 (en) 2006-10-20 2007-10-18 Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US44604109A Continuation-In-Part 2006-10-20 2009-08-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/560,257 Continuation US8338376B2 (en) 2006-10-20 2009-09-15 Compositions comprising variant LT-B-R-IG fusion proteins

Publications (2)

Publication Number Publication Date
WO2008112325A2 WO2008112325A2 (en) 2008-09-18
WO2008112325A3 true WO2008112325A3 (en) 2009-12-23

Family

ID=39630536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003548 WO2008112325A2 (en) 2006-10-20 2008-03-17 Treatment of autoimmune disorders

Country Status (5)

Country Link
EP (1) EP2139509A2 (en)
JP (1) JP5431171B2 (en)
CN (1) CN101951940A (en)
CA (1) CA2680792A1 (en)
WO (1) WO2008112325A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090071652A (en) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor
BRPI0908270A2 (en) * 2008-02-29 2019-09-10 Biogen Idec Inc purified immunoglobulin fusion proteins and method for their purification
CA2737379A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
WO2012064792A2 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CR20170510A (en) 2015-04-10 2018-02-26 Amgen Inc INTERUQUINE MUTEINS 2 FOR THE EXPANSION OF REGULATORY T-CELLS
EP3900716A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003687A1 (en) * 1995-07-21 1997-02-06 Biogen, Inc. SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE
WO2000036092A2 (en) * 1998-12-17 2000-06-22 Biogen, Inc. METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION
US6087126A (en) * 1998-06-19 2000-07-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2006007853A2 (en) * 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
US20070036806A1 (en) * 2003-06-12 2007-02-15 Eli Lilly And Company Glp-1 analog fusion proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700317B2 (en) * 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
DK1639014T3 (en) * 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
CA2536408A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
KR20090071652A (en) * 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor
MX2009012343A (en) * 2007-05-14 2010-02-10 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto.
BRPI0908270A2 (en) * 2008-02-29 2019-09-10 Biogen Idec Inc purified immunoglobulin fusion proteins and method for their purification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003687A1 (en) * 1995-07-21 1997-02-06 Biogen, Inc. SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE
US6087126A (en) * 1998-06-19 2000-07-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000036092A2 (en) * 1998-12-17 2000-06-22 Biogen, Inc. METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION
US20070036806A1 (en) * 2003-06-12 2007-02-15 Eli Lilly And Company Glp-1 analog fusion proteins
WO2006007853A2 (en) * 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHANDKE K M ET AL: "INFLUENCE OF IONS ON CYCLIZATION OF THE AMINO TERMINAL GLUTAMINE RESIDUES OF TRYPTIC PEPTIDES OF STREPTOCOCCAL PEPM49 PROTEIN RESOLUTION OF CYCLIZED PEPTIDES BY HPLC AND CHARACTERIZATION BY MASS SPECTROMETRY", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 34, no. 2, 1989, pages 118 - 123, XP002538251, ISSN: 0367-8377 *
See also references of EP2139509A2 *

Also Published As

Publication number Publication date
EP2139509A2 (en) 2010-01-06
JP2010521472A (en) 2010-06-24
CA2680792A1 (en) 2008-09-18
WO2008112325A2 (en) 2008-09-18
CN101951940A (en) 2011-01-19
JP5431171B2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
WO2008112325A3 (en) Treatment of autoimmune disorders
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
JO2576B1 (en) Antibodies
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2007007173A3 (en) Human anti-madcam antibodies
WO2008121767A3 (en) Stitched polypeptides
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2006083971A3 (en) Dr5 antibodies and uses thereof
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
WO2012061558A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2012061374A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2012027570A3 (en) Dual variable domain immunoglobulins and uses thereof
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
WO2008011603A3 (en) Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2009038673A3 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880016341.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742126

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2680792

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009553656

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008742126

Country of ref document: EP